Resveratrol-mediated attenuation of superantigen-driven acute respiratory distress syndrome is mediated by microbiota in the lungs and gut.
Animals
Anti-Inflammatory Agents
/ pharmacology
Cell Line
Colon
/ drug effects
Cytokines
/ metabolism
Disease Models, Animal
Dysbiosis
Enterotoxins
Fecal Microbiota Transplantation
Female
Gastrointestinal Microbiome
/ drug effects
Inflammation Mediators
/ metabolism
Limosilactobacillus reuteri
/ drug effects
Lung
/ drug effects
Mice, Inbred C3H
Respiratory Distress Syndrome
/ immunology
Resveratrol
/ pharmacology
Superantigens
ARDS
Cytokine storm
DiOC(6)(3) (3,3′-Dihexyloxacarbocyanine iodide, PubChem CID: 9894321)
Microbiota
Resveratrol
SEB
Superantigen
butyric acid (PubChem CID: 264)
carboxymethylcellulose (PubCID: 24748)
interleukin 1beta (PubChem CID: 159483)
iso butyric acid (PubChem CID: 6590) and acetic acid (PubChem CID: 176)
lipopolysaccharide (LPS, PubChem CID: 451715)
metronidazole (Bioxtra, PubChem CID: 24896667)
propionic acid (PubChem CID: 1032)
resveratrol (PubChem CID: 445154)
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
04
08
2020
revised:
23
02
2021
accepted:
09
03
2021
pubmed:
17
3
2021
medline:
6
5
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
Acute Respiratory Distress Syndrome (ARDS) is triggered by a variety of agents, including Staphylococcal Enterotoxin B (SEB). Interestingly, a significant proportion of patients with COVID-19, also develop ARDS. In the absence of effective treatments, ARDS results in almost 40% mortality. Previous studies from our laboratory demonstrated that resveratrol (RES), a stilbenoid, with potent anti-inflammatory properties can attenuate SEB-induced ARDS. In the current study, we investigated the role of RES-induced alterations in the gut and lung microbiota in the regulation of ARDS. Our studies revealed that SEB administration induced inflammatory cytokines, ARDS, and 100% mortality in C3H/HeJ mice. Additionally, SEB caused a significant increase in pathogenic Proteobacteria phylum and Propionibacterium acnes species in the lungs. In contrast, RES treatment attenuated SEB-mediated ARDS and mortality in mice, and significantly increased probiotic Actinobacteria phylum, Tenericutes phylum, and Lactobacillus reuteri species in both the colon and lungs. Colonic Microbiota Transplantation (CMT) from SEB-injected mice that were treated with RES as well as the transfer of L. reuteri into recipient mice inhibited the production of SEB-mediated induction of pro-inflammatory cytokines such as IFN-γ and IL-17 but increased that of anti-inflammatory IL-10. Additionally, such CMT and L. reuteri recipient mice exposed to SEB, showed a decrease in lung-infiltrating mononuclear cells, cytotoxic CD8+ T cells, NKT cells, Th1 cells, and Th17 cells, but an increase in the population of regulatory T cells (Tregs) and Th3 cells, and increase in the survival of mice from SEB-mediated ARDS. Together, the current study demonstrates that ARDS induced by SEB triggers dysbiosis in the lungs and gut and that attenuation of ARDS by RES may be mediated, at least in part, by alterations in microbiota in the lungs and the gut, especially through the induction of beneficial bacteria such as L. reuteri.
Identifiants
pubmed: 33722710
pii: S1043-6618(21)00132-8
doi: 10.1016/j.phrs.2021.105548
pmc: PMC10116750
mid: NIHMS1891633
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Enterotoxins
0
Inflammation Mediators
0
Superantigens
0
enterotoxin B, staphylococcal
39424-53-8
Resveratrol
Q369O8926L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105548Subventions
Organisme : NIEHS NIH HHS
ID : R01 ES030144
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103641
Pays : United States
Organisme : NCCIH NIH HHS
ID : P01 AT003961
Pays : United States
Organisme : NCCIH NIH HHS
ID : R01 AT006888
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123947
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Microb Cell Fact. 2013 Jul 23;12:71
pubmed: 23876056
Gut Microbes. 2020 Jul 3;11(4):997-1014
pubmed: 32138622
Blood Adv. 2018 Jul 10;2(13):1651-1663
pubmed: 29991496
Med Res Rev. 2019 Nov;39(6):2286-2313
pubmed: 30994937
Environ Microbiol. 2016 Sep;18(8):2646-59
pubmed: 27312602
J Cell Mol Med. 2019 Dec;23(12):8101-8113
pubmed: 31559687
Int J Mol Sci. 2020 Aug 28;21(17):
pubmed: 32872332
Br J Pharmacol. 2012 Nov;167(6):1244-58
pubmed: 22646800
Crit Rev Food Sci Nutr. 2014;54(6):734-70
pubmed: 24345046
Int J Obes (Lond). 2020 Jan;44(1):213-225
pubmed: 30718820
BMC Pulm Med. 2020 Feb 22;20(1):49
pubmed: 32087725
Microsc Microanal. 2012 Jun;18(3):445-452
pubmed: 22571856
Pharm Biol. 2020 Dec;58(1):8-15
pubmed: 31847682
Biomed Res Int. 2013;2013:804391
pubmed: 24308006
J Cell Mol Med. 2018 May;22(5):2644-2655
pubmed: 29512867
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
JAMA. 2018 Feb 20;319(7):698-710
pubmed: 29466596
Front Immunol. 2018 Dec 20;9:2992
pubmed: 30619345
Saudi J Biol Sci. 2018 Jan;25(1):44-46
pubmed: 29379355
Br J Pharmacol. 2020 Nov;177(22):5078-5095
pubmed: 32754917
Res Vet Sci. 2009 Apr;86(2):241-7
pubmed: 18793785
Appl Environ Microbiol. 2004 Oct;70(10):6166-72
pubmed: 15466563
Biomedicines. 2018 Sep 09;6(3):
pubmed: 30205595
Bioinformatics. 2018 Apr 15;34(8):1411-1413
pubmed: 29028892
Hum Cell. 2020 Jan;33(1):67-78
pubmed: 31784954
Free Radic Biol Med. 2019 May 1;135:38-45
pubmed: 30807829
Appl Environ Microbiol. 2017 Dec 15;84(1):
pubmed: 29054873
Infect Immun. 2011 Aug;79(8):3141-8
pubmed: 21628519
Foods. 2020 Mar 14;9(3):
pubmed: 32183376
Med Sci Monit. 2019 Sep 29;25:7312-7320
pubmed: 31563920
Nutrients. 2017 May 31;9(6):
pubmed: 28561758
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Int Immunopharmacol. 2020 Mar;80:106152
pubmed: 31926447
ACS Infect Dis. 2018 Jan 12;4(1):14-26
pubmed: 29207239
Front Pharmacol. 2020 Jun 16;11:893
pubmed: 32612530
Am J Emerg Med. 2018 Aug;36(8):1486-1491
pubmed: 29804790
Scand J Immunol. 2020 Mar;91(3):e12855
pubmed: 31793015
Annu Rev Microbiol. 2016 Sep 8;70:235-54
pubmed: 27607553
Brain Behav Immun. 2019 Nov;82:25-35
pubmed: 31356922
Int Immunopharmacol. 2020 Jun;83:106369
pubmed: 32163900
J Leukoc Biol. 2019 Aug;106(2):467-480
pubmed: 30897248
Eur J Immunol. 2020 Mar;50(3):326-337
pubmed: 31991477
Mucosal Immunol. 2017 Mar;10(2):299-306
pubmed: 27966551
Food Funct. 2020 Jan 29;11(1):1063-1073
pubmed: 31825043
Nutrients. 2018 Nov 03;10(11):
pubmed: 30400297
3 Biotech. 2020 Feb;10(2):52
pubmed: 32015948
Int J Mol Sci. 2020 Dec 17;21(24):
pubmed: 33348596
World J Gastroenterol. 2020 Feb 28;26(8):777-788
pubmed: 32148376
Front Microbiol. 2018 Apr 19;9:757
pubmed: 29725324
Immunity. 2020 Feb 18;52(2):241-255
pubmed: 32075727
Microbiol Spectr. 2013 Dec;1(2):
pubmed: 26184960
PLoS One. 2020 Apr 21;15(4):e0231865
pubmed: 32315360
Cell Metab. 2017 Oct 3;26(4):672-685.e4
pubmed: 28918936
Infect Immun. 2005 Jan;73(1):50-61
pubmed: 15618140
Biomolecules. 2019 Jun 11;9(6):
pubmed: 31212626
PLoS One. 2013;8(2):e56547
pubmed: 23437165
Microbiol Mol Biol Rev. 2015 Nov 25;80(1):1-43
pubmed: 26609051